FDA Biosimilar Education Campaign Will Need To Be Targeted
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.
You may also be interested in...
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says
Material to help providers and patients understand scientific issues can inspire more confidence in the products, exec says.